Acer Medical, a spinoff of Acer focusing on AI in healthcare, has achieved another milestone in its AI strategy. On July 16, the company announced a partnership with Japan’s Fujitsu to co-develop a new solution named “aiGait powered by UvanceAI.” The solution utilizes Fujitsu’s high-precision AI skeletal recognition technology to analyze patients’ physical movements and gait abnormalities, helping healthcare professionals detect early signs of dementia and Parkinson’s disease, thereby improving clinical diagnosis and intervention efficiency. Acer Medical plans to roll out the solution across elderly care institutions and primary clinics in Taiwan by the end of this year.

Fujitsu’s AI skeletal recognition model is based on data collected from its gymnastics judging support system. Its proprietary calibration algorithm significantly reduces posture estimation errors—an issue commonly encountered in deep learning image analysis when identifying characteristic movements of dementia and Parkinson’s patients. In addition, Fujitsu leverages synthetic image generation technology to produce large volumes of training data, drastically shortening model training time. Tasks that used to require months of manual processing can now be completed within hours through automated workflows.

According to Acer Medical, the agreement was officially signed on June 25, 2025. Initial testing will begin at the Day Care Center affiliated with Taipei Veterans General Hospital. The system will use cameras to capture daily movements such as standing, sitting, and walking. With the support of AI skeletal recognition, it will analyze and assess the risk of dementia by comparing observed movements with known patterns. The system will generate user-friendly reports and alert caregivers when significant gait deviations occur, recommending further evaluation by a physician.

Acer Medical emphasized that the collaboration with Fujitsu will accelerate solutions to societal issues related to abnormal gait—especially as it is considered a potential early indicator of dementia and Parkinson’s disease. The two companies aim to promote this solution across Taiwan’s long-term care facilities and primary care clinics to improve accessibility for elderly care. They also plan to expand the technology's application to areas such as sports science analysis, pediatric neurodevelopmental disorders, and cerebral palsy.

Acer Medical continues to enhance its capabilities in AI-assisted medical devices. It recently announced that its AI diagnostic software for abnormal bone mineral density, VeriOsteo OP, has received market approval from Singapore’s Health Sciences Authority. Chairman Allen Lien previously stated that with several medical devices receiving new certifications, and with both the healthcare industry and medical institutions actively pursuing smart healthcare transformation, the company is aiming for strong growth momentum both domestically and internationally this year.

Resource: 宏碁小金雞 開發新AI醫療應用